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Case Reports
Characterization and Treatment of Unilateral Facial Muscle Spasm in Linear
Scleroderma: A Case Report
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Abstract
Background: Linear scleroderma has been associated with muscle spasms ipsilateral to skin lesions. Typically, spasms are located in trigeminal innervated muscles,
leading to hemimasticatory spasm (HMS).
Case Report: We report a case of linear scleroderma associated with spasm of muscles innervated not only by the trigeminal but also by the facial nerve.
Discussion: We review the patient’s successful treatment with incobotulinumtoxinA, a formulation of botulinum toxin that has not been reported for use in this
condition.
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Introduction
Linear scleroderma is a chronic connective tissue disease character-
ized by skin lesions in the face and neck. These lesions are char-
acterized as en coup de sabre, vertical, colorless skin indentations that
resemble a wound from being struck by a sword.1,2 These involve the
deep and superficial layers of the skin and can impair motion of the
underlying joints. Linear scleroderma has been associated with
hemimasticatory spasm (HMS) in a number of cases.3
HMS is characterized by involuntary muscle spasms of the jaw-
closing muscles on one side of the face.4 One defining electrophysio-
logical characteristic of HMS is the absence of silent periods during
times of involuntary spasms.5 HMS is thought to be due to focal
demyelination at the motor root or the motor nucleus of the trigeminal
nerve,6 or from injury to the motor fibers of the trigeminal nerve from
deep tissue changes caused by linear scleroderma7 or dental proce-
dures.3 It affects the trigeminal innervated muscles, including the
temporalis, masseter, and medial and lateral pterygoid muscles.8
Hemifacial spasm (HFS) is a far more common condition char-
acterized by spasms of the muscle fibers innervated by the ipsilateral
facial nerve.9 The two types of HFS include idiopathic and secondary
HFS. Idiopathic HFS is in some cases thought to be caused by nerve
compression at the root exit point whereas secondary HFS can be
triggered by any other damage to the facial nerve, including prior
Bell’s palsy, effects of demyelination in multiple sclerosis, and from
conditions known to cause cranial neuropathies such as Lyme disease
and sarcoidosis. The average age of onset is 44.10
Botulinum toxin A has been successfully used to treat symptoms of
dystonia, HFS, and HMS due to a variety of etiologies.11–13
Case report
We report a previously healthy Caucasian man diagnosed at age 30
with linear scleroderma. He developed facial spasms about 2 years
after the onset of the skin lesions. Both the skin lesions and the muscle
spasms occurred only on the left side. The patient was aware of these
muscle contractions, which led to emotional distress and social
withdrawal.
The muscle spasms at first occurred randomly, and after a few
months became nearly constant throughout the waking day; these
spasms resulted in teeth chattering and involuntary movements of the
jaw up to several times an hour.
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The spasms were exacerbated by touch such as lying on the left side
of his face. These spasms could be suppressed for a couple of seconds
by the patient tightening all his upper and lower facial musculature
into a forceful grimace and were partially relieved by chewing, such as
the use of gum. The spasms caused considerable discomfort, but were
not painful. There was no urge to move or a build-up of inner tension
before these involuntary muscle contractions. No sensory symptoms
were reported by the patient.
General examination revealed a band of sclerotic skin over the left
brow and along the left corner of the mouth. Muscle spasms presented
as rippling movements beneath the skin in the muscles identified
clinically as the left temporalis, masseter, frontalis, depressor supercilii,
risorius, zygomaticus, depressor labii inferioris, and depressor anguli oris.
The left temporalis and masseter muscles were markedly hypertrophic.
Myokymic discharges and dystonic muscle contractions were identi-
fied based on the typical audio signature on the needle electromyo-
graphy of grouped repetitive discharges and sustained tonic discharges.
Dystonic contractions were predominantly noted in the masseter and
temporalis; myokymic discharges and non-sustained tonic discharges
were noted in the frontalis, risorius, zygomaticus, and depressor anguli
oris muscles.
Thus far, the patient has received 22 injection sessions of incobo-
tulinumtoxinA (Xeomin, Merz) over the past 6 years. His initial dose
was 30 units and it has been increased over time to 45 units (Figure 1).
A seven-point semiquantitative outcome scale was used before each of
the 22 injection sessions (0 5 no disability to 6 5 completely incapac-
itated) (Table 1). Scoring was based on patient report and the examiner’s
assessment. This analysis is performed routinely in the clinic before all
botulinum toxin injections, in all patients, for any indication.
N The patient scored 5 (severe disability or functional impairment)
before the initial injection.
N At his best level of function after receiving botulinum toxin
injections, the patient averaged a score of 0.14 across 22 injections.
Figure 1. Typical Injection Sites under EMG Guidance.
IncobotulinumtoxinA. . 5 2.5 u/0.05 mL; : 5 5 u/0.1 mL; :: 5 10 u/0.2 mL.
Table 1. Outcome Scale Based on Patient Report and Examiner’s Assessment Performed at Each Botulinum Injection Session
Current (pre-injection) disability
0 No disability or functional impairment
1 Mild disability or functional impairment
2 Mild–moderate disability or functional impairment
3 Moderate disability or functional impairment
4 Moderate–severe disability or functional impairment
5 Severe disability or functional impairment
6 Completely incapacitated
Disability at patient’s best following last botulinum toxin injection session
0 No disability or functional impairment
1 Mild disability or functional impairment
2 Mild–moderate disability or functional impairment
3 Moderate disability or functional impairment
4 Moderate–severe disability or functional impairment
5 Severe disability or functional impairment
6 Completely incapacitated
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N The duration of effect of each injection was approximately
10.9 weeks.
N There was an average of 15.1 weeks between each injection.
N At the time of injection, the effects of botulinum toxin injections
had partially worn off and the patient averaged a score of 3.73 across
the 22 injections.
Since the start of the injections, the patient has experienced marked
relief from the involuntary muscle spasms and hypertrophy.
Discussion
There have been no reports on the effective use of incobotuli-
numtoxinA in HMS. IncobotulinumtoxinA is a low molecular weight
formulation of botulinum toxin type A free of non-toxin complexing
proteins.
As opposed to classically defined HMS, non-trigeminal innervated
muscles have been identified in our patient, and have also been
injected with botulinum toxin with good results. There have only been
a few cases of HMS described in the literature, and only one case,
to our knowledge, in which non-trigeminal innervated muscles are
involved.14
Our report suggests that the effects of linear scleroderma can extend
to other non-trigeminal innervated muscle groups, which would sup-
port the proposed pathophysiologic mechanism of localized injury to
the motor fibers from the deep tissue changes caused by linear sclero-
derma. We show that botulinum toxin therapy with incobotulinu-
mtoxinA can be used safely and effectively over several years.
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